Vaxcyte

Today we announced positive topline results from the Phase 1/2 study of VAX-31, our 31-valent pneumococcal conjugate vaccine (PCV) candidate, in healthy adults aged 50 and older. We are exceptionally proud to share these results, which we believe validate VAX-31’s potential as a best-in-class pneumococcal vaccine capable of raising the bar for immunogenicity standards. The public health community continues to highlight the need for broader-protection vaccines to prevent invasive pneumococcal disease, which is associated with high case-fatality rates, antibiotic resistance and meningitis. To address this need, VAX-31 was designed to increase coverage to more than 95% of IPD circulating in adults 50 and older in the United States, with the potential to provide significantly greater coverage relative to today’s standard-of-care adult PCVs.   We want to extend a sincere thank you to everyone involved in this program, especially trial investigators, trial sites, study participants and the entire Vaxcyte team.   For more, read the full press release here: https://lnkd.in/g72D5AUd  #Vaccines #Biotechnology #ProtectHumankind #PCV

Today we announced positive topline results from the Phase 1/2 study of VAX-31, our 31-valent pneumococcal conjugate vaccine (PCV) candidate, in healthy adults aged 50 and older. We are exceptionally proud to share these results, which we believe validate VAX-31’s potential as a best-in-class pneumococcal vaccine capable of raising the bar for immunogenicity standards. The public health community continues to highlight the need for broader-protection vaccines to prevent invasive pneumococcal disease, which is associated with high case-fatality rates, antibiotic resistance and meningitis. To address this need, VAX-31 was designed to increase coverage to more than 95% of IPD circulating in adults 50 and older in the United States, with the potential to provide significantly greater coverage relative to today’s standard-of-care adult PCVs.   We want to extend a sincere thank you to everyone involved in this program, especially trial investigators, trial sites, study participants and the entire Vaxcyte team.   For more, read the full press release here: https://lnkd.in/g72D5AUd  #Vaccines #Biotechnology #ProtectHumankind #PCV

We are proud to share that Andrew Guggenhime, our President and CFO, has been named a finalist for the Bay Area CFO of the Year Awards presented by the San Francisco Business Times in partnership with Larkin Street Youth Services. This recognition is a testament to Andrew’s exceptional leadership, strategic vision and his unwavering dedication to delivering on our mission to protect humankind from the consequences of bacterial diseases. It’s also a reflection of the incredible work of our entire team, whose passion and commitment drive our shared success. Head here to learn more about the awards, the finalists and Larkin Street Youth Services, a leading Bay Area nonprofit empowering homeless and at-risk youth: https://lnkd.in/gbPEAG2G #BayAreaCFOAwards

As the summer comes to a close, we want to give a huge thanks to all of our 2024 summer interns for their hard work, dedication and enthusiasm these past few months! Our interns have been working at our San Carlos headquarters across various departments including finance, facilities, protein development, supply chain, CMC and immunoassay. We’re passionate about developing the next generation of biotech leaders and giving students an opportunity to gain valuable hands-on work experience to complement their college curriculum. #biotech #interns [From left to right: Avery Tuthill, Rachna Balasubramanian Maya Narang Vijini Liyanage, Surabhi Pandey and Donovan Pareja-jimenez (not pictured: Katherine Brenner).]

We are pleased to share that the VAX-24 Phase 2 study in adults aged 65 and older has been published in the medical journal Vaccine. The publication of these positive results is a testament to the potential of VAX-24, our 24-valent pneumococcal conjugate vaccine (PCV), as well as our cell-free technology in developing carrier-sparing vaccines. Our PCV candidates, VAX-24 and VAX-31, our 31-valent PCV, are designed to deliver the broadest-spectrum of coverage to protect against invasive pneumococcal disease (IPD) in adults and infants while maintaining coverage of the historically circulating strains. Congratulations to the authors of this important publication. https://lnkd.in/dzNssgYU

Pipetting - the Olympic sport you’ve never heard of. In honor of the Summer Olympics, we recently hosted our first-ever Pipette Olympics during which our talented team members competed in three group-based events — the pipette tip toss, pipette painting and pipette relay. The competition was fierce, leading to a speed pipetting tiebreaker. Congratulations to our gold medalist, early-stage Analytical Development/Conjugation team, who took pipetting to a whole new level! Shoutout to our silver and bronze medalists on the Analytical and Drug Product teams. Thank you to everyone who participated and made this event unforgettable! #culture #team #pipette #olympics #summerolympics

We are pleased to share our second quarter 2024 business and financial update as we continue to make significant strides in advancing our pneumococcal conjugate vaccine candidates, VAX-24 and VAX-31. We look forward to sharing VAX-31 adult Phase 1/2 study topline data in September, which will provide significant insights into the full potential of this vaccine candidate across the adult population.   Additionally, we expect to share VAX-24 infant Phase 2 study topline data by the end of the first quarter of 2025, followed by topline data from the booster dose by the end of 2025. We believe VAX-24 has a potential best-in-class profile for this vital population and is designed to cover more serotypes than any infant pneumococcal vaccine on-market today.   Read more here: https://lnkd.in/g7J7ywWm #biotechnology #vaccines #publichealth

Annette Makarewycz, Vaxcyte's Vice President of Talent Acquisition, reflects on her decision to join our team earlier this year, and what makes our company unique. This includes celebrating Vaxcyte being recognized by Great Place to Work as the # 1 ranked biotech on the Best Small and Medium Workplaces in the Bay Area list. Learn more below and explore our current job listings: vaxcyte.com/job-listings/ #hiring #biotech #vaccines #culture

We are thrilled to share that we have been recognized by Great Place to Work as one of the Best Small and Medium Workplaces in the Bay Area for the second year in a row! This year, we are #11 overall and the #1-ranked biotech in our category. At Vaxcyte, we lead with heart to achieve bold goals and are grateful to the entire team for making this company such a special place to work. Check out our Great Place to Work page: https://lnkd.in/gxPHBaSb    Interested in joining our growing team? Learn more at vaxcyte.com/job-listings/ #GreatPlacetoWork #culture #biotech

Vaxcyte’s cell-free protein synthesis platform enables us to overcome limitations of traditional chemistry and develop potentially superior and novel vaccine candidates. With this unique technology, we are advancing our broad-spectrum pneumococcal conjugate vaccine candidates, VAX-24 and VAX-31, that are designed to prevent invasive pneumococcal disease, as well as vaccines to potentially address bacterial diseases like Group A Strep and Shigella for which there are no preventative treatments.   Vaxcyte's Chief Executive Officer and Co-Founder Grant Pickering and Vice President of Research and Co-Founder Jeff Fairman share more about our platform, as well as our team's chemistry, which fuels our collaborative culture and drives our innovation. Learn more at vaxcyte.com/approach  #VaccineInnovation #vaccines #culture